Your browser doesn't support javascript.
loading
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study.
Zhou, Fei; Guo, Haoyue; Zhou, Xiaolong; Xie, Huikang; Tian, Tian; Zhao, Wencheng; Gao, Guanghui; Xiong, Anwen; Wang, Lei; Li, Wei; Chen, Xiaoxia; Zhang, Yan; Fan, Jue; Wu, Fengying; Zhang, Yongchang; Zhou, Caicun.
Afiliación
  • Zhou F; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Guo H; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Zhou X; Department of Ultrasound in Medicine, Yiyang Central Hospital, Yiyang, Hunan, China.
  • Xie H; Department of Pathology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Tian T; Department of Respiratory Oncology, Anhui Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Zhao W; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Gao G; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Xiong A; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Wang L; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Li W; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Chen X; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Zhang Y; Singleron Biotechnologies, Nanjing, Jiangsu, China.
  • Fan J; Singleron Biotechnologies, Nanjing, Jiangsu, China.
  • Wu F; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Yangpu District, Shanghai 200433, China.
  • Zhang Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, No 283 Tongzipo Road, Yuelu District, Changsha, 410013, Hunan, China.
  • Zhou C; Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Yangpu District, Shanghai 200433, China.
Ther Adv Med Oncol ; 14: 17588359221136759, 2022.
Article en En | MEDLINE | ID: mdl-36419724
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Ther Adv Med Oncol Año: 2022 Tipo del documento: Article País de afiliación: China